GlaxoSmithKline (NYSE:GSK) has filed for Food and Drug Administration approval of fluticasone furoate, an asthma treatment.
The British company’s once-a-day inhaled corticosteroid treatment would be administered by the the Ellipta dry powder inhaler. GSK is seeking approval for fluticasone furoate monotherapy as a maintenance treatment of asthma in patients 12 years old and older.
GSK plans to file for approval of the treatment in other countries next year. GSK operates its U.S. headquarters in Research Triangle Park.
